Millipore And Oxford Immunotec Co-Develop Plates For Diagnosing And Monitoring Infections

Billererica, MA, USA and Oxford, UK, 21 September 2005 – Millipore Corporation (NYSE:MIL) and Oxford Immunotec Ltd. announced today the co-development of a specially designed microtitre plate for use in clinical diagnostics kits. The new plate further advances the simplicity, cost-effectiveness and performance of Oxford Immunotec’s proprietary T-SPOTTM technology.

This is the first 8-well strip-based plate customised for use in Enzyme-Linked Immunospot (ELISPOT) methodology compared with typical 96-well plates. It is more economical for users to select the number of wells they require and reduce waste as a result. Utilizing Millipore’s market-leading ELISPOT technology with Immobilon®-P membrane, users can rely on the quality and accuracy of the product.

Dr. Peter Wrighton-Smith, CEO of Oxford Immunotec commented, “We have been consistently impressed by Millipore as a collaboration partner. They have delivered a state-of-the art product on time and on budget. Pairing our pre-eminent T-SPOT technology for diagnosing and monitoring infectious diseases with a flexible multi-well platform is a key step forward in integrating this test worldwide.

Oxford Immunotec will incorporate the plate into a second generation of its T-SPOT.TB test kit, a revolutionary new test for tuberculosis. It is set to replace the 100-year old skin test currently used to diagnose this resurgent disease. Incorporating the new plate will provide greater flexibility and improved performance, while lowering the cost of administering the test.

“Millipore is committed to aligning itself with technology leaders, such as Oxford Immunotec, for the delivery of leading-edge products,” said Jonathan DiVincenzo, Vice President of R&D and Marketing for Millipore’s Bioscience Division. “The first use of the new plate is a test that will greatly improve the control of one of the world’s most profound health problems.”

The two companies entered into this partnership in September 2004. Currently, the plates are in production. Under the terms of the agreement, Oxford Immunotec has exclusive rights to use the plates for in vitro diagnostics with its T-SPOT assay kits.